Market Closed -
Euronext Paris
09:05:14 26/04/2024 pm IST
|
5-day change
|
1st Jan Change
|
3.444
EUR
|
-0.06%
|
|
-5.95%
|
-27.03%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
233.7
|
704.9
|
2,574
|
861.1
|
655.1
|
478
|
-
|
-
|
Enterprise Value (EV)
1 |
195.5
|
553.9
|
2,286
|
670.5
|
737.8
|
512.5
|
566
|
591.9
|
P/E ratio
|
-129
x
|
-10.9
x
|
-32.7
x
|
-5.02
x
|
-6.47
x
|
23.3
x
|
-41.7
x
|
-18.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
0.29%
|
-
|
Capitalization / Revenue
|
1.85
x
|
6.39
x
|
7.4
x
|
2.38
x
|
4.26
x
|
2.48
x
|
2.05
x
|
1.48
x
|
EV / Revenue
|
1.55
x
|
5.02
x
|
6.57
x
|
1.86
x
|
4.8
x
|
2.66
x
|
2.42
x
|
1.84
x
|
EV / EBITDA
|
25.1
x
|
-12.3
x
|
-48.5
x
|
-9.69
x
|
-11.3
x
|
9.52
x
|
-22.8
x
|
-228
x
|
EV / FCF
|
-36.5
x
|
4.68
x
|
-140
x
|
-2.44
x
|
-3.4
x
|
-36.6
x
|
-258
x
|
172
x
|
FCF Yield
|
-2.74%
|
21.4%
|
-0.71%
|
-41%
|
-29.4%
|
-2.74%
|
-0.39%
|
0.58%
|
Price to Book
|
1.73
x
|
9.09
x
|
15.1
x
|
-
|
-
|
2.18
x
|
4.07
x
|
4.83
x
|
Nbr of stocks (in thousands)
|
90,920
|
90,958
|
1,05,078
|
1,38,355
|
1,38,788
|
1,38,788
|
-
|
-
|
Reference price
2 |
2.570
|
7.750
|
24.50
|
6.224
|
4.720
|
3.444
|
3.444
|
3.444
|
Announcement Date
|
27/02/20
|
25/02/21
|
03/02/22
|
23/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
126.2
|
110.3
|
348.1
|
361.3
|
153.7
|
192.4
|
233.7
|
322
|
EBITDA
1 |
7.8
|
-45.2
|
-47.1
|
-69.2
|
-65.24
|
53.82
|
-24.81
|
-2.591
|
EBIT
1 |
-0.811
|
-55.12
|
-61.4
|
-113.4
|
-82.09
|
31.72
|
-32.5
|
5.123
|
Operating Margin
|
-0.64%
|
-49.97%
|
-17.64%
|
-31.4%
|
-53.4%
|
16.49%
|
-13.91%
|
1.59%
|
Earnings before Tax (EBT)
1 |
-0.87
|
-65.3
|
-69.98
|
-144.8
|
-98.63
|
22.66
|
-33.85
|
-6.817
|
Net income
1 |
-1.7
|
-64.4
|
-73.4
|
-143.3
|
-101.4
|
25.44
|
-33.17
|
-15.29
|
Net margin
|
-1.35%
|
-58.39%
|
-21.09%
|
-39.66%
|
-65.99%
|
13.22%
|
-14.19%
|
-4.75%
|
EPS
2 |
-0.0200
|
-0.7100
|
-0.7500
|
-1.240
|
-0.7300
|
0.1475
|
-0.0825
|
-0.1867
|
Free Cash Flow
1 |
-5.355
|
118.3
|
-16.27
|
-274.7
|
-217
|
-14.02
|
-2.198
|
3.439
|
FCF margin
|
-4.24%
|
107.22%
|
-4.67%
|
-76.02%
|
-141.16%
|
-7.29%
|
-0.94%
|
1.07%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
0.0100
|
-
|
Announcement Date
|
27/02/20
|
25/02/21
|
03/02/22
|
23/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
47.91
|
22.3
|
278.3
|
21.8
|
71.4
|
93.2
|
156.7
|
111.4
|
33.51
|
40.19
|
38.07
|
41.9
|
66.6
|
37.95
|
43.24
|
52.22
|
EBITDA
|
-
|
-
|
12.54
|
-13.3
|
-122.7
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-21.93
|
-151.4
|
11.1
|
-18.4
|
-128.8
|
-147.2
|
93.32
|
-56.35
|
-16.57
|
-20.28
|
-22.21
|
-24.91
|
77.38
|
-20.01
|
-15.97
|
-15.64
|
Operating Margin
|
-45.77%
|
-679.15%
|
3.99%
|
-84.4%
|
-180.39%
|
-157.94%
|
59.55%
|
-50.58%
|
-49.46%
|
-50.46%
|
-58.35%
|
-59.45%
|
116.19%
|
-52.71%
|
-36.93%
|
-29.96%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-0.1300
|
-0.1200
|
-0.2500
|
-0.2300
|
0.6000
|
-0.0900
|
-0.1200
|
-0.1100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
04/08/20
|
18/11/21
|
03/02/22
|
05/05/22
|
11/08/22
|
11/08/22
|
10/11/22
|
23/03/23
|
04/05/23
|
21/09/23
|
09/11/23
|
21/03/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
82.7
|
34.5
|
88
|
114
|
Net Cash position
1 |
38.1
|
151
|
289
|
191
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-1.268
x
|
0.6409
x
|
-3.546
x
|
-43.95
x
|
Free Cash Flow
1 |
-5.36
|
118
|
-16.3
|
-275
|
-217
|
-14
|
-2.2
|
3.44
|
ROE (net income / shareholders' equity)
|
-1.25%
|
-60.6%
|
-59.2%
|
-73.4%
|
-58.3%
|
16%
|
-37.9%
|
-17.9%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
1.490
|
0.8500
|
1.620
|
-
|
-
|
1.580
|
0.8500
|
0.7100
|
Cash Flow per Share
2 |
0.0600
|
0.9500
|
-
|
-0.8600
|
-
|
-0.1000
|
-0.1000
|
0.1000
|
Capex
1 |
10.5
|
18.9
|
92.2
|
29.2
|
14.2
|
13.9
|
11.7
|
9.32
|
Capex / Sales
|
8.32%
|
17.17%
|
26.49%
|
8.09%
|
9.26%
|
7.25%
|
4.99%
|
2.89%
|
Announcement Date
|
27/02/20
|
25/02/21
|
03/02/22
|
23/03/23
|
21/03/24
|
-
|
-
|
-
|
Last Close Price
3.444
EUR Average target price
8.95
EUR Spread / Average Target +159.87% Consensus |
1st Jan change
|
Capi.
|
---|
| -27.03% | 510M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|